{
    "comments": "Larazotide (AT1001) is an eight amino acid oligopeptide. Its sequence is derived from the zonula occludens toxin that is secreted by <i>Vibrio cholerae</i>. In human tissues larazotide acts to restore the intercellular tight junction complex <Reference id=48573/><Reference id=48572/> and regulates epithelial and endothelial permeability by antagonising the effects of zonulin on the tight junction protein 1 (<a href=\"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11827\" target=\"_blank\"><i>TJP1</i></a>). Larazotide was proposed for potential therapeutic application in celiac disease where tight junctions and intestinal permeability are dysregulated <Reference id=48569/><Reference id=48571/><Reference id=48574/>.",
    "bioactivityComments": "",
    "clinicalUse": "Larazotide was initially investigated in clinical trials to determine safety and efficacy as a treatment for Coeliac disease <Reference id=48569/><Reference id=48571/>, but development was discontinued at phase 3. It has subsequently been repositioned for potential to treat long COVID.",
    "mechanismOfAction": "",
    "absorptionAndDistribution": "",
    "metabolism": "",
    "elimination": "",
    "populationPharmacokinetics": "",
    "organFunctionImpairment": "",
    "immuno": "",
    "gtmp": ""
}